{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:44:13Z","timestamp":1791182653532,"version":"4.1.0"},"reference-count":23,"publisher":"American Veterinary Medical Association (AVMA)","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To assess the impact of clopidogrel or rivaroxaban administration on recurrence of arterial thromboembolism (ATE) in cats that have recovered from cardiogenic ATE.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS <\/jats:title>\n<jats:p>This multicenter prospective double-masked protocol enrolled 45 cats that had recovered from cardiogenic ATE and were randomized to receive either clopidogrel (18.75 mg\/cat, PO; n = 19) or rivaroxaban (2.5 mg\/cat, PO; 26) as sole anticoagulant therapy for up to 2 years after the initial ATE. Primary outcome measures included recurrent ATE or death from any cause. In addition to bimonthly internet-based surveys of animal quality of life, echocardiograms were performed by veterinary cardiologists at 2, 6, 12, and 18 months after initial ATE. <\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS <\/jats:title>\n<jats:p>17 cats experienced ATE recurrence: 7 of 19 (37%) in the clopidogrel group and 10 of 26 (39%) in the rivaroxaban group. Three cats in each group survived for the entire 2-year study without recurrence. In the clopidogrel group, median (95% CI) time to ATE recurrence was 663 days (150 to not calculable) and in the rivaroxaban group, 513 days (242 to not calculable). Median time from enrollment to death from cardiac or noncardiac causes was also not different between treatment groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CONCLUSIONS <\/jats:title>\n<jats:p>Single-agent antithrombotic therapy with rivaroxaban in cats recovered from cardiogenic embolism delayed recurrence of ATE for a similar time period as single-agent therapy with clopidogrel. <\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CLINICAL RELEVANCE <\/jats:title>\n<jats:p>In cats that have recovered from cardiogenic ATE, either rivaroxaban or clopidogrel may be used for single-agent thromboprophylaxis to delay ATE recurrence.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.24.09.0584","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:23:41Z","timestamp":1734528221000},"page":"1-10","source":"Crossref","is-referenced-by-count":10,"title":["Therapy with clopidogrel or rivaroxaban has equivalent impacts on recurrence of thromboembolism and survival in cats following cardiogenic thromboembolism: the SUPERCAT study"],"prefix":"10.2460","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-2936","authenticated-orcid":true,"given":"Benjamin M.","family":"Brainard","sequence":"first","affiliation":[{"name":"Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda E.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Royal Veterinary College, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Rush","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjory B.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Kraus","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"11","key":"ref1","series-title":"J Am Vet Med Assoc","first-page":"1398","article-title":"Prevalence of cardiomyopathy in apparently healthy cats","volume":"234","author":"Paige CF","year":"2009","unstructured":"Paige CF, Abbott JA, Elvinger F, Pyle RL. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc. 2009;234(11):1398-1403. doi:10.2460\/javma.234.11.1398"},{"key":"ref2","series-title":"Textbook of Canine and Feline Cardiology: Principles and Clinical Practice","first-page":"621","article-title":"Feline cardiomyopathy","author":"Fox PR","year":"1999","unstructured":"Fox PR, Sisson D, Moise NS. Feline cardiomyopathy. In: Fox PR, ed. Textbook of Canine and Feline Cardiology: Principles and Clinical Practice. 2nd ed. W. B. Saunders Co; 1999:621-678."},{"issue":"3","key":"ref3","series-title":"J Vet Intern Med","first-page":"546","article-title":"Hypercoagulability in cats with cardiomyopathy","volume":"22","author":"Stokol T","year":"2008","unstructured":"Stokol T, Brooks M, Rush JE,  Hypercoagulability in cats with cardiomyopathy. J Vet Intern Med. 2008;22(3):546-552. doi:10.1111\/j.1939-1676.2008.0098.x"},{"issue":"6","key":"ref4","series-title":"J Vet Intern Med","first-page":"1427","article-title":"Prognostic indicators in cats with hypertrophic cardiomyopathy","volume":"27","author":"Payne JR","year":"2013","unstructured":"Payne JR, Borgeat K, Connolly DJ,  Prognostic indicators in cats with hypertrophic cardiomyopathy. J Vet Intern Med. 2013;27(6):1427-1436. doi:10.1111\/jvim.12215"},{"issue":"1","key":"ref5","series-title":"J Vet Intern Med","first-page":"73","article-title":"Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases","volume":"17","author":"Smith SA","year":"2003","unstructured":"Smith SA, Tobias AH, Jacob KA, Fine DM, Grumbles PL. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med. 2003;17(1):73-83."},{"issue":"suppl 1","key":"ref6","series-title":"J Vet Cardiol","first-page":"S306","article-title":"Secondary prevention of cardiogenic arterial thromboembolism in the cat: the double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT)","volume":"17","author":"Hogan DF","year":"2015","unstructured":"Hogan DF, Fox PR, Jacob K,  Secondary prevention of cardiogenic arterial thromboembolism in the cat: the double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT). J Vet Cardiol. 2015;17(suppl 1):S306-S317. doi:10.1016\/j.jvc.2015.10.004"},{"issue":"2","key":"ref7","series-title":"J Vet Intern Med","first-page":"411","article-title":"Platelet activation in cats with hypertrophic cardiomyopathy","volume":"28","author":"Tablin F","year":"2014","unstructured":"Tablin F, Schumacher T, Pombo M,  Platelet activation in cats with hypertrophic cardiomyopathy. J Vet Intern Med. 2014;28(2):411-418. doi:10.1111\/jvim.12325"},{"issue":"8","key":"ref8","series-title":"J Am Vet Med Assoc","first-page":"1237","article-title":"Use of low molecular weight heparin in cats: 57 cases (1999-2003)","volume":"225","author":"Smith CE","year":"2004","unstructured":"Smith CE, Rozanski EA, Freeman LM, Brown DJ, Goodman JS, Rush JE. Use of low molecular weight heparin in cats: 57 cases (1999-2003). J Am Vet Med Assoc. 2004;225(8):1237-1241. doi:10.2460\/javma.2004.225.1237"},{"issue":"9","key":"ref9","series-title":"J Am Vet Med Assoc","first-page":"1406","article-title":"Antiplatelet effects and pharmacodynamics of clopidogrel in cats","volume":"225","author":"Hogan DF","year":"2004","unstructured":"Hogan DF, Andrews DA, Green HW, Talbott KK, Ward MP, Calloway BM. Antiplatelet effects and pharmacodynamics of clopidogrel in cats. J Am Vet Med Assoc. 2004;225(9):1406-1411. doi:10.2460\/javma.2004.225.1406"},{"issue":"3","key":"ref10","series-title":"J Vet Intern Med","first-page":"378","article-title":"Anticoagulant effects of low-molecular-weight heparins in healthy cats","volume":"21","author":"Alwood AJ","year":"2007","unstructured":"Alwood AJ, Downend AB, Brooks MB,  Anticoagulant effects of low-molecular-weight heparins in healthy cats. J Vet Intern Med. 2007;21(3):378-387."},{"issue":"4","key":"ref11","series-title":"J Feline Med Surg","first-page":"277","article-title":"Dual therapy with clopidogrel and rivaroxaban in cats with thromboembolic disease","volume":"24","author":"Lo ST","year":"2022","unstructured":"Lo ST, Walker AL, Georges CJ, Li RH, Stern JA. Dual therapy with clopidogrel and rivaroxaban in cats with thromboembolic disease. J Feline Med Surg. 2022;24(4):277-283. doi:10.1177\/1098612X211013736"},{"issue":"4","key":"ref12","series-title":"Clin Pharmacol Ther","first-page":"412","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza D","year":"2005","unstructured":"Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-421. doi:10.1016\/j.clpt.2005.06.011"},{"issue":"10","key":"ref13","series-title":"N Engl J Med","first-page":"883","article-title":"ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi:10.1056\/NEJMoa1009638"},{"issue":"5","key":"ref14","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"619","article-title":"Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats","volume":"26","author":"Dixon-Jimenez AC","year":"2016","unstructured":"Dixon-Jimenez AC, Brainard BM, Brooks MB,  Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats. J Vet Emerg Crit Care (San Antonio). 2016;26(5):619-629. doi:10.1111\/vec.12524"},{"issue":"9","key":"ref15","series-title":"Xenobiotica","first-page":"891","article-title":"Pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014in rats and dogs","volume":"35","author":"Weinz C","year":"2005","unstructured":"Weinz C, Buetehorn U, Daehler HP,  Pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014in rats and dogs. Xenobiotica. 2005;35(9):891-910. doi:10.1080\/00498250500250493"},{"issue":"12","key":"ref16","series-title":"Eur J Clin Pharmacol","first-page":"873","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza D","year":"2005","unstructured":"Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880. doi:10.1007\/s00228-005-0043-5"},{"issue":"3","key":"ref17","series-title":"Thromb Haemost","first-page":"453","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck W","year":"2008","unstructured":"Mueck W, Borris LC, Dahl OE,  Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100(3):453-461."},{"key":"ref18","series-title":"J Vet Cardiol","first-page":"77","article-title":"Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers","volume":"30","author":"Coleman AE","year":"2020","unstructured":"Coleman AE, DeFrancesco TC, Griffiths EH,  Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers. J Vet Cardiol. 2020;30:77-91. doi:10.1016\/j.jvc.2020.06.002"},{"issue":"10","key":"ref19","series-title":"J Thromb Haemost","first-page":"2017","article-title":"Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study","volume":"15","author":"Kreutz R","year":"2017","unstructured":"Kreutz R, Persson PB, Kubitza D,  Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. J Thromb Haemost. 2017;15(10):2017-2028. doi:10.1111\/jth.13801"},{"issue":"5","key":"ref20","series-title":"J Vet Intern Med","first-page":"1601","article-title":"Effect of body weight on echocardiographic measurements in 19,866 pure-bred cats with or without heart disease","volume":"30","author":"H\u00e4ggstr\u00f6m J","year":"2016","unstructured":"H\u00e4ggstr\u00f6m J, Andersson \u00c5O, Falk T,  Effect of body weight on echocardiographic measurements in 19,866 pure-bred cats with or without heart disease. J Vet Intern Med. 2016;30(5):1601-1611. doi:10.1111\/jvim.14569"},{"issue":"2","key":"ref21","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"158","article-title":"Spontaneous echocardiographic contrast in three dogs","volume":"21","author":"Ralph AG","year":"2011","unstructured":"Ralph AG, Saunders AB, Hariu CD, Nabity M. Spontaneous echocardiographic contrast in three dogs. J Vet Emerg Crit Care (San Antonio). 2011;21(2):158-165. doi:10.1111\/j.1476-4431.2011.00624.x"},{"issue":"1","key":"ref22","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"88","article-title":"Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 5\u2014discontinuation of anticoagulant therapy in small animals","volume":"29","author":"Brainard BM","year":"2019","unstructured":"Brainard BM, Buriko Y, Good J, Ralph AG, Rozanski EA. Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 5\u2014discontinuation of anticoagulant therapy in small animals. J Vet Emerg Crit Care (San Antonio). 2019;29(1):88-97. doi:10.1111\/vec.12796"},{"issue":"4","key":"ref23","series-title":"J Thromb Haemost","first-page":"1016","article-title":"Dual antithrombotic therapy dose-dependently alters hemostatic plug structure and function","volume":"22","author":"Mansi CD","year":"2024","unstructured":"Mansi CD, Severa JR, Wilhelm JN,  Dual antithrombotic therapy dose-dependently alters hemostatic plug structure and function. J Thromb Haemost. 2024;22(4):1016-1023. doi:10.1016\/j.jtha.2023.12.017"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/263\/4\/javma.24.09.0584.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/263\/4\/javma.24.09.0584.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/263\/4\/javma.24.09.0584.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T02:28:58Z","timestamp":1742869738000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/263\/4\/javma.24.09.0584.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":23,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.2460\/javma.24.09.0584","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}